Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study

Lung Cancer

Volumn 81, Issue 2, 2013, Pages 280-287

  Wu, Yi Long ^a   Fukuoka, Masahiro ^b   Mok, Tony S K ^c   Saijo, Nagahiro ^b   Thongprasert, Sumitra ^d   Yang, James C H ^e   Chu, Da Tong ^f   Yang, Jin Ji ^a   Rukazenkov, Yuri ^g  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d Faculty of Medicine Chiang Mai University   (Thailand)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f CANCER HOSPITAL   (China)

^g ASTRAZENECA   (United Kingdom)

Author keywords

EGFR mutation; EGFR TKI; Gefitinib; NSCLC

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASIA; CANCER SIZE; CONTROLLED STUDY; DRUG ERUPTION; DRUG SAFETY; FEMALE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE;

EGFR MUTATION; EGFR-TKI; GEFITINIB; NSCLC;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIA; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EXANTHEMA; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PACLITAXEL; QUALITY OF LIFE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84879884557     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.03.004     Document Type: Article

References (33)

1. Jemal A. Cancer statistics 2011. CA Cancer J Clin 2011, 61:69-90.
2. Cooley M.E. Symptoms in adults with lung cancer: a systematic research review. J Pain Symptom Manage 2000, 19:137-153.
3. Natale R.B., Skarin A., Maddox A.-M., Hammond L.A., Thomas R., Gandara D.R., et al. Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2. Proc Am Soc Clin Oncol 2002, 21. Abstract 1167.
4. Cella D., Herbst R.S., Lynch T.J., Prager D., Belani C.P., Schiller J.H., et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol 2005, 23:2946-2954.
5. Gettinger S., Lynch T. A decade of advances in treatment for advanced non-small cell lung cancer. Clin Chest Med 2011, 32:839-851.
6. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
7. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
8. Mok T.S., Wu Y.-L., Thongprasert S., Yang C.-H., Chu D.-T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
9. Han J.Y., Park K., Kim S.W., Lee D.H., Kim H.Y., Kim H.T., et al. First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012, 30:1122-1128.
10. Fukuoka M., Wu Y.-L., Thongprasert S., Sunpaweravong P., Leong S.-S., Sriuranpong V., et al. Biomarker analyses and final overall survival results from a Phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011, 29:2866-2874.
11. Thongprasert S., Duffield E., Saijo N., Wu Y.-L., Yang C.-H., Chu D.-T., et al. Health-related quality-of-life in a randomized Phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol 2011, 6:1872-1880.
12. Perez-Soler R., Van Cutsem E. Clinical research of EGFR inhibitors and related dermatologic toxicities. Oncology (Williston Park) 2007, 21(Suppl 5):10-16.
13. Rukazenkov Y., Speake G., Marshall G., Anderton J., Davies B.R., Wilkinson R.W., et al. Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?. Anticancer Drugs 2009, 20:856-866.
14. Wacker B., Nagrani T., Weinberg J., Witt K., Clark G., Cagnoni P.J. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007, 13:3913-3921.
15. Zhu Y.J., Xia Y., Ren G.J., Wang M.Z., Zeng X., Zhang L. Efficacy and clinical/molecular predictors of erlotinib monotherapy for Chinese advanced non-small cell lung cancer. Chin Med J (Engl) 2010, 123:3200-3205.
16. Dudek A.Z., Kmak K.L., Koopmeiners J., Keshtgarpour M. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer 2006, 51:89-96.
17. Mohamed M.K., Ramalingam S., Lin Y., Gooding W., Belani C.P. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol 2005, 16:780-785.
18. West H.L., Franklin W.A., McCoy J., Gumerlock P.H., Vance R., Lau D.H., et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol 2006, 24:1807-1813.
19. Fukuoka M., Kris M., Giaccone G., Lynch T., Nakagawa K., Kelly K., et al. Phase II trials of gefitinib ('Iressa', ZD1839): rapid and durable objective responses in patients with advanced non-small-cell lung cancer (IDEAL 1 and IDEAL 2). Lung Cancer 2003, 41(Suppl 2). S247, P-615.
20. Kris M.G., Natale R.B., Herbst R.S., Lynch T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA 2003, 290:2149-2158.
21. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
22. Newton C.R., Graham A., Heptinstall L.E., Powell S.J., Summers C., Kalsheker N., et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 1989, 17:2503-2516.
23. Whitcombe D., Theaker J., Guy S.P., Brown T., Little S. Detection of PCR products using self-probing amplicons and fluorescence. Nat Biotechnol 1999, 17:804-807.
24. Cella D.F., Bonomi A.E., Lloyd S.R., Tulsky D.S., Kaplan E., Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995, 12:199-220.
25. Cella D., Eton D.T., Fairclough D.L., Bonomi P., Heyes A.E., Silberman C., et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 2002, 55:285-295.
26. Bearz A., Vaccher E., Spazzapan S., Berretta M., Tirelli U. Gefitinib in patients with non-small cell lung cancer: symptomatic improvement within a few days. Lung Cancer 2005, 49:417-418.
27. Suspitsin E.N., Levchenko E.V., Moiseyenko F.V., Ivantsov A.O., Radzhabova S.A., Matsko D.E., et al. Rapid symptomatic improvement in gefitinib-treated patients with EGFR-mutated lung cancer: possible role of downregulation of inflammatory molecules?. Onkologie 2011, 34:559-560.
28. Ruddy K., Mayer E., Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009, 59:56-66.
29. Jackman D.M., Miller V.A., Cioffredi L.A., Yeap B.Y., Janne P.A., Riely G.J., et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009, 15:5267-5273.
30. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.-Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003, 21:2237-2246.
31. Wang X.S., Shi Q., Lu C., Basch E.M., Johnson V.E., Mendoza T.R., et al. Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer. Cancer 2010, 116:137-145.
32. De Marinis F., Pereira J.R., Fossella F., Perry M.C., Reck M., Salzberg M., et al. Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer. J Thorac Oncol 2008, 3:30-36.
33. Galetta D., Pisconti S., Cinieri S., Pappagallo G.L., Gebbia V., Borsellino N., et al. Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized Phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE). Clin Lung Cancer 2011, 12:402-406.